Gujarat Themis Biosyn sees indirect encumbrance via 2.5 mn pledged shares of PBGIL

What Gujarat Themis Biosyn disclosed

On 1 July 2026, CTL Trusteeship Limited filed a disclosure under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 with the Bombay Stock Exchange. The filing, made on behalf of the debenture trustee, informs the market that an indirect encumbrance has been created over shares of Gujarat Themis Biosyn Limited (the Target Company). The encumbrance arises from a pledge and a non‑disposal undertaking over equity shares of Pharmaceutical Business Group (India) Limited (PBGIL), which are held by Vividhmargi Investments Private Limited (VIPL). No direct acquisition of Gujarat Themis Biosyn shares has taken place.

Details of the encumbrance

• Pledge: 2,524,245 equity shares of PBGIL, representing 51 % of PBGIL’s issued and paid‑up share capital, were pledged on 29 June 2026 in favour of the debenture trustee.
• Non‑disposal undertaking: 2,157,855 equity shares of PBGIL, representing 47.988 % of PBGIL’s issued and paid‑up share capital, were subject to a non‑disposal undertaking on the same date.
• Indirect effect: Both the pledged shares and the non‑disposal undertaking are held by VIPL, which in turn holds a controlling stake in PBGIL. The filing notes that this creates an indirect encumbrance on the shares of Gujarat Themis Biosyn, although the exact number of Gujarat Themis Biosyn shares held by PBGIL is not disclosed.
• Equity capital of Gujarat Themis Biosyn: The company’s total equity share capital remains unchanged at Rs 10,89,65,265, comprising 10,89,65,265 fully paid‑up equity shares of Rs 1 each.

Parties involved

Regulatory framework

Regulation 29(1) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 mandates that any person or entity acquiring shares—or creating an encumbrance that could affect voting rights—must disclose the transaction to the stock exchange within a prescribed time‑frame. The purpose is to ensure transparency for shareholders and the market, especially where the acquisition or encumbrance could lead to a change in control.

In this case, the creation of a pledge and a non‑disposal undertaking over a majority of PBGIL’s share capital is deemed material because it may indirectly affect the voting power attached to Gujarat Themis Biosyn shares held by PBGIL. Consequently, CTL Trusteeship Ltd filed the required disclosure with BSE, which was subsequently made public on 2 July 2026.

Key facts at a glance

Why this matters for investors

The disclosure does not alter the number of Gujarat Themis Biosyn shares outstanding, nor does it indicate any immediate change in the company’s ownership structure. However, the indirect encumbrance means that a substantial portion of the voting power attached to shares held by PBGIL is now subject to a pledge and a non‑disposal undertaking. Should the debenture trustee enforce its rights, the pledged shares could be realized, potentially affecting the control dynamics of PBGIL and, by extension, any voting rights that PBGIL exercises in Gujarat Themis Biosyn. Investors should monitor any subsequent filings that may disclose a direct acquisition or a change in the pledged status.

Conclusion

The filing made on 1 July 2026 by CTL Trusteeship Ltd under SEBI’s Regulation 29(1) informs the market of an indirect encumbrance on Gujarat Themis Biosyn shares through pledged and non‑disposal shares of PBGIL. No direct share acquisition has occurred, and the company’s equity capital remains unchanged. The disclosure satisfies regulatory transparency requirements, and further developments—such as the possible conversion of the pledged debentures into equity—would be communicated in future filings.